Cargando…
Current status of biosimilars in the treatment of inflammatory bowel diseases
Introduction of biological therapies have led to dramatic changes in the management of debilitating immune-mediated inflammatory bowel diseases (IBD) including ulcerative colitis and Crohn's disease. However, the long term use of these agents may be very expensive, placing a significant burden...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Korean Association for the Study of Intestinal Diseases
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4754516/ https://www.ncbi.nlm.nih.gov/pubmed/26884730 http://dx.doi.org/10.5217/ir.2016.14.1.15 |